Skip to main content

Advertisement

Table 3 (A) Treatment-emergent non-hematologic adverse events occurring in greater than 10% of patients and (B) Grade 3–4 hematologic abnormalities (N = 46)

From: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

(A)
  Severity grade, n (%)
Preferred term 1 2 3 4 Overall (N = 46)
Fatigue 9 (20) 8 (17) 2 (4) 0 19 (41)
Headache 14 (30) 2 (4) 0 0 16 (35)
Chills 11 (24) 3 (7) 1 (2) 0 15 (33)
Pyrexia 8 (17) 4 (9) 0 0 12 (26)
Nausea 8 (17) 2 (4) 1 (2) 0 11 (24)
Diarrhoea 8 (17) 1 (2) 0 0 9 (20)
Dyspnoea 4 (9) 5 (11) 0 0 9 (20)
Cough 7 (15) 0 0 0 7 (15)
Back pain 3 (7) 2 (4) 1 (2) 0 6 (13)
Depression 4 (9) 2 (4) 0 0 6 (13)
Musculoskeletal pain 4 (9) 2 (4) 0 0 6 (13)
Abdominal pain 1 (2) 2 (4) 2 (4) 0 5 (11)
Asthenia 2 (4) 2 (4) 1 (2) 0 5 (11)
Constipation 5 (11) 0 0 0 5 (11)
Oedema peripheral 4 (9) 1 (2) 0 0 5 (11)
Oropharyngeal pain 5 (11) 0 0 0 5 (11)
Vomiting 2 (4) 2 (4) 1 (2) 0 5 (11)
(B)
  Grade 3 Grade 4
  n (%) n (%)
Lymphopenia 14 (30) 5 (11)
Neutropenia 5 (11) 1 (2)
Thrombocytopenia 7 (15) 2 (4)
Leukopenia 6 (13) 1 (2)